The Board of Directors of Aurobindo Pharma Limited (the Company) at its meeting held today i.e. February 27 2021 has approved the following:
1) Transfer of all equity shares held in Lyfius Pharma Private Limited a wholly owned subsidiary of the Company to Aurobindo Antibiotics Private Limited another wholly owned subsidiary of the Company.
2) Transfer of all equity shares held in Qule Pharma Private Limited a wholly owned subsidiary of the Company to Aurobindo Antibiotics Private Limited another wholly owned subsidiary of the Company.
3) Transfer of business undertaking comprised in Unit-10 on a going concern basis to APL Healthcare Limited a wholly owned subsidiary of the Company.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
